Drugs / Cell-culture
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT04583995 | Sep 2020 → Mar 2022 | COVID-19 | Novavax | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03598439 | Jul 2018 → Mar 2020 | influenza | Marshfield Clinic Research Foundation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cell-culture | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03598439 ↗ |
| Known as | Flucelvax Quadrivalent | “quadrivalent influenza cell-based vaccine [Flucelvax Quadrivalent; Seqirus UK, Maidenhead] for those aged 18-64 years” PMID 34800364 ↗ Nov 2021 |
| Modality | Vaccine | “licensed cell-culture influenza vaccine” NCT03598439 ↗ |
| Route | Intramuscular | “a single (0·5 mL) intramuscular, age-appropriate (quadrivalent influenza cell-based vaccine [Flucelvax Quadrivalent; Seqirus UK, Maidenhead]” PMID 34800364 ↗ Nov 2021 |